Experimental eye drug shows promise for rare Blindness-Causing disease
NCT ID NCT06852963
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called VP-001 for people with a rare genetic eye disease that causes vision loss. The drug is injected into the eye and aims to slow or stop further damage. Researchers will check safety and measure any changes in eyesight over about two years. The trial includes 17 adults who have already received VP-001 in earlier studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EYE DISEASES, HEREDITARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bascom Palmer Eye Institute - University of Miami
Miami, Florida, 33136, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Casey Eye Institute - OHSU
Portland, Oregon, 97239, United States
-
Kellogg Eye Center - University of Michigan
Ann Arbor, Michigan, 48105, United States
-
Retina Foundation of the Southwest
Dallas, Texas, 75231, United States
-
University of Florida College of Medicine
Jacksonville, Florida, 32209, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single eye injection restore sight in genetic blindness?
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Stem cell eye transplant aims to halt blindness from rare genetic disease
- Could a smartphone camera spot blinding eye diseases?
- Could stem cells restore sight in damaged eyes?
- New eye scanner aims to sharpen view of retinal disease